Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro

World Journal of Gastroenterology

Volumn 11, Issue 17, 2005, Pages 2643-2646

  Jin, Yong ^a   Li, Jun ^a   Rong, Long Fu ^a   Li, Yuan Hai ^a   Guo, Lin ^a   Xu, Shu Yun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

5 fluorouracil; Anti hepatocarcinoma; Galactosylceramide; Liposome

Indexed keywords

FLUOROURACIL; GALACTOSYLCERAMIDE; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG FORMULATION; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR FLUID; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; MOUSE STRAIN; NONHUMAN;

EID: 18944404490     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i17.2643     Document Type: Article

References (21)

1. Kubota T. Theoretical basis for low-dose CDDP/5-FU therapy. Jpn J Cancer Chemother 1999; 26: 1536-1541
2. Benson AB 3rd. Therapy for advanced colorectal cancer. Semi Oncol 1998; 25: 2-11
3. Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res 2000; 60: 3717-3721
4. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hoshimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 1029-1037
5. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001; 61: 4937-4941
6. Kuropkat C, Griem K, Clark J, Rodriguez ER, Hutchinson J, Taylor SG 4th. Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report. Am J Clin Oncol 1999; 22: 466-470
7. Fata F, Ron IG, Kemeny N, O'Reilly E, Klimstra D, Kelsen DP. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 1999; 86: 1129-1134
8. van Kuilenburg AB, Haasjes J, Richel D, Zoetekouw L, Van Lenthe H, De Abreu RA, Maring JG, Vreken P, van Gennip AH. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712
9. Di Paolo A, Danesi R, Falcone A, Cionini L, Vannozzi F, Masi G, Allegrini G, Mini E, Bocci G, Conte PF, Del Tacca M. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. Ann Oncol 2001; 12: 1301-1306
10. Kuan HY, Smith DE, Ensminger WD, Knol JA, DeRemer SJ, Yang Z, Stetson PL. Regional pharmacokinetics of 5-fluorouracil in dogs: role of the liver, gastrointestinal tract, and lungs. Cancer Res 1998; 58: 1688-1694
11. Martini LG, Collett JH, Attwood D. The release of 5-fluorouracil from microspheres of poly (epsilon-caprolactone-coethylene oxide). Drug Dev Ind Pharm 2000; 26: 7-12
12. Hagiwara A, Sakakura C, Shirasu M, Yamasaki J, Togawa T, Takahashi T, Muranishi S, Hyon S, Ikada Y. Therapeutic effects of 5-fluorouracil microspheres on peritoneal carcinomatosis induced by Colon 26 or B-16 melanoma in mice. Anticancer Drug 1998; 9: 287-289
13. Jing M, Xi S, Chen R. The inhibitory effect of tissue plasminogen activator combined with 5-fluorouracil polyphase liposome on the scar formation in experimental filtration surgery. Zhonghua Yanke Zazhi 1997; 33: 376-380
14. Wang G, Tucker IG, Roberts MS, Hirst LW. In vitro and in vivo evaluation in rabbits of a controlled release 5-fluorouracil subconjunctival implants base on poly (D, L-lactide-coglycoside). Pharm Res 1996; 13: 1059-1064
15. Umejima H, Kikuchi A, Kim NS, Uchida T, Goto S. Preparation and evaluation of Eudragit gels. VIII. Rectal absorption of 5-fluorouracil from Eudispert hv gels in rats. J Pharm Sci 1995; 84: 199-202
16. Jung M, Berger G, Pohlen U, Pauser S, Reszka R, Buhr HJ. Simultaneous determination of 5-fluorouracil and its active metabolites in serum and tissue by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 702: 193-202
17. Joulia JM, Pinguet F, Grosse PY, Astre C, Bressolle F. Determination of 5-fluorouracil and its main metabolites in plasma by high-performance liquid chromatography: Application to a pharmacokinetic study. J Chromatogr B Biomed Sci Appl 1997; 692: 427-435
18. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995; 13: 527-537
19. Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 1993; 46: 618-638
20. Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 2000; 43: 197-205
21. Nishikawa M, Hirabayashi H, Takakura Y, Hashida M. Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharm Res 1995; 12: 209-214